PureTech Hopes For A Second Lightning Strike

Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?    

Clouds-Lightning-Storm_1200x675

PureTech Health plc has made no secret of its ambition to use Karuna Therapeutics, Inc. as a blueprint for the development of new portfolio companies. In Seaport Therapeutics, which formally launched yesterday with a $100m series A round, it is doing exactly that.

Seaport is aiming to treat disorders including depression and anxiety, where Karuna was focused on schizophrenia. But both follow the same strategy of tweaking older drugs and repurposing them for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

Immusoft Goes For Cell Therapy Plan ‘B’

 

Emerging Company Profile: CEO Sean Ainsworth spoke with Scrip about how the company is developing B-cell therapies to treat a range of diseases, starting with MPS I.

Sanofi-Backed Resalis Brings MicroRNA To Obesity

 

Emerging Company Profile: Resalis will soon start human trials of an oligonucleotide targeting a microRNA that is overexpressed in obese mice, but much remains to be proven in humans.

Volastra Aims To Terminate Cancer Relying On Chromosomal Instability

 

Emerging Company Profile: Volastra is testing two KIF18A inhibitors in early clinical trials in ovarian cancer, backed by investors like Polaris Partners and ARCH Ventures.

Seraxis Takes Its Islet Cell Tech Into The Clinic

 

Emerging Company Profile: The Maryland-based biotech is working on a functional cure for type 1 diabetes that is similar to Vertex’s VX-880 – but with some key differences.

More from Start-Ups & SMEs

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By 

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.